Cytogenetic analysis of 280 patients with multiple myeloma and related disorders: primary breakpoints and clinical correlations

MJ Calasanz, JC Cigudosa, MD Odero… - Genes …, 1997 - Wiley Online Library
MJ Calasanz, JC Cigudosa, MD Odero, C Ferreira, MT Ardanaz, A Fraile, JL Carrasco
Genes, Chromosomes and Cancer, 1997Wiley Online Library
Cytogenetic analysis of unstimulated short-term bone marrow cell cultures was performed
on 280 patients with multiple myeloma and related disorders. In 65% of the cases, an
additional short term B-cell stimulated culture was also examined. Chromosomally abnormal
clones were found in 31% of the patients, 15% in Waldenström macroglobulinemia, 25% in
monoclonal gammopathies, 33% in multiple myeloma, and 50% in plasma cell leukemia.
Three primary chromosomal breakpoints were recurrently involved: 14q32, 16q22, and …
Abstract
Cytogenetic analysis of unstimulated short-term bone marrow cell cultures was performed on 280 patients with multiple myeloma and related disorders. In 65% of the cases, an additional short term B-cell stimulated culture was also examined. Chromosomally abnormal clones were found in 31% of the patients, 15% in Waldenström macroglobulinemia, 25% in monoclonal gammopathies, 33% in multiple myeloma, and 50% in plasma cell leukemia. Three primary chromosomal breakpoints were recurrently involved: 14q32, 16q22, and 22q11. Structural rearrangements of chromosome I were the most frequent (26% of the abnormal cases), but always as a secondary change. Rearrangements of band 14q32 were found in 22% of the abnormal cases. Among the multiple myeloma patients who showed an abnormal karyotype, 33 (46%) were hyperdiploid, most frequently with 52–56 chromosomes, 29 patients (40%) were pseudodiploid, and the remaining 12 cases (14%) were hypodiploid. A highly significant relation was observed between the presence of an abnormal karyotype and the following clinical parameters: stage III (P= 0.0001), bone marrow plasma cell infiltration greater than 30%(P= 0.0001), presence of bone lesions (P= 0.0009), and β2-microglobulin levels greater than 4 mg/L (P= 0.0001). Genes Chromosom. Cancer 18: 84–93, 1997.© 1997 Wiley-Liss, Inc.
Wiley Online Library